Our Services
Medical Information
Helpful Resources
Published on: 9/15/2026
Stage 1 fatty liver, also called simple steatosis, is the earliest and most reversible stage, but in some people it can progress over years to inflammation (steatohepatitis), fibrosis, cirrhosis, and, less commonly, liver cancer. Progression risk depends on several factors, including ongoing alcohol use, type 2 diabetes, obesity, high triglycerides, genetics, viral hepatitis, and how long the fat has been present, and cancer can occasionally develop even without full cirrhosis. Weight loss of 7 to 10%, blood sugar and cholesterol control, alcohol reduction, and regular monitoring can reverse early damage and halt the pathway to cirrhosis. There are important details, warning signs, and timelines to consider, so review the complete answer below rather than the summary alone.
Because early liver disease is usually silent and symptoms like fatigue, upper right abdominal discomfort, or swelling can point in many directions, a free, instant, online symptom check can help you understand what your symptoms may mean and which tests or specialists to ask about next.
Last reviewed for medical accuracy: 09/14/2026
Fatty liver disease stage 1—also called simple steatosis—is when small amounts of fat build up in liver cells without causing significant inflammation or scarring. It’s common, especially in people with obesity, type 2 diabetes or metabolic syndrome. The good news is that stage 1 fatty liver is generally reversible. But left unchecked, it can progress to more serious conditions, including cirrhosis and even liver cancer.
Below is an overview of:
Natural history of fatty liver
Risk of progression
Factors that speed up progression
While most people with stage 1 fatty liver never develop cirrhosis or HCC, you shouldn’t ignore it. Early intervention is key to stopping or even reversing the process.
Reversing stage 1 fatty liver focuses on reducing fat in liver cells and improving metabolic health. Clinical guidelines (National Institutes of Health, NIDDK) emphasize lifestyle changes as first-line therapy.
Regular monitoring helps detect any worsening early, so you can adjust your plan.
If you experience any of the following, speak with a healthcare professional promptly:
For a quick check, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you decide when to seek in-person care.
If you have concerns about liver disease or any serious symptoms, please speak to a doctor. Early medical advice can be life-saving and help you maintain a healthy liver for years to come.
(References)
* Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021 Jun 5;397(10290):2212-2224. doi: 10.1016/S0140-6736(20)32511-3. Epub 2021 Apr 21. PMID: 33894145.
* Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021 May 13;184(10):2537-2564. doi: 10.1016/j.cell.2021.04.015. PMID: 33989548; PMCID: PMC12168897.
* Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenwälder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol. 2022 Oct;77(4):1136-1160. doi: 10.1016/j.jhep.2022.06.012. Epub 2022 Jun 22. PMID: 35750137.
* Han SK, Baik SK, Kim MY. Non-alcoholic fatty liver disease: Definition and subtypes. Clin Mol Hepatol. 2023 Feb;29(suppl):S5-S16. doi: 10.3350/cmh.2022.0424. Epub 2022 Dec 28. PMID: 36577427; PMCID: PMC10029964.
* Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023 Aug;79(2):516-537. doi: 10.1016/j.jhep.2023.03.017. Epub 2023 Mar 27. PMID: 36990226.
* Terrault NA, Francoz C, Berenguer M, Charlton M, Heimbach J. Liver Transplantation 2023: Status Report, Current and Future Challenges. Clin Gastroenterol Hepatol. 2023 Jul;21(8):2150-2166. doi: 10.1016/j.cgh.2023.04.005. Epub 2023 Apr 20. PMID: 37084928.
* Younossi ZM, Wong G, Anstee QM, Henry L. The Global Burden of Liver Disease. Clin Gastroenterol Hepatol. 2023 Jul;21(8):1978-1991. doi: 10.1016/j.cgh.2023.04.015. Epub 2023 Apr 28. PMID: 37121527.
* Jeong BK, Choi WI, Choi W, Moon J, Lee WH, Choi C, Choi IY, Lee SH, Kim JK, Ju YS, Kim P, Moon YA, Park JY, Kim H. A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma. Nat Commun. 2024 Aug 2;15(1):6506. doi: 10.1038/s41467-024-50660-y. Epub 2024 Aug 2. PMID: 39090079; PMCID: PMC11294468.
* Hagström H, Shang Y, Hegmar H, Nasr P. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol. 2024 Oct;9(10):944-956. doi: 10.1016/S2468-1253(24)00193-6. PMID: 39243773.
* Tilg H, Petta S, Stefan N, Targher G. Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review. JAMA. 2026 Jan 13;335(2):163-174. doi: 10.1001/jama.2025.19615. PMID: 41212550.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.